BRILINTA is a P2Y12 platelet inhibitor indicated
• to reduce the risk of cardiovascular (CV) death, myocardial infarction (MI),
and stroke in patients with acute coronary syndrome (ACS) or a history of
MI. For at least the first 12 months following ACS, it is superior to
clopidogrel.
BRILINTA also reduces the risk of stent thrombosis in patients who have
been stented for treatment of ACS.
• to reduce the risk of a first MI or stroke in patients with coronary artery
disease (CAD) at high risk for such events. While use is not limited to this
setting, the efficacy of BRILINTA was established in a population with
type 2 diabetes mellitus (T2DM).
• to reduce the risk of stroke in patients with acute ischemic stroke (NIH
Stroke Scale score ≤5) or high-risk transient ischemic attack (TIA).
